Premium
Hypolipidemic effect of myricetin in db/db mice
Author(s) -
Choi HaNeul,
Jang YangHee,
Kang MinJung,
Kim JungIn
Publication year - 2013
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.27.1_supplement.855.3
Subject(s) - myricetin , dyslipidemia , cholesterol , christian ministry , medicine , endocrinology , diabetes mellitus , fenofibrate , type 2 diabetes , chemistry , biochemistry , antioxidant , kaempferol , philosophy , theology , quercetin
Aggressive treatment of dyslipidemia is associated with the reduced risk for cardiovascular diseases in diabetic patients. The aim of this study was to investigate the effect of myricetin on dyslipidemia in animal model of type 2 diabetes. Four‐week‐old male C57BL/KsJ‐db/db mice (n=14) were fed AIN‐93G diet or diet containing myricetin (150 mg/kg) for 7 weeks after one week of adaptation. After the animals were sacrificed after an overnight‐fast, serum triglycerides, total cholesterol, and HDL‐cholesterol were measured by enzymatic methods. Atherogenic index (AI) was calculated as follows: [(Total cholesterol ‐ HDL‐cholesterol)/HDL‐cholesterol]. Myricetin decreased serum triglycerides and total cholesterol levels compared with the control group (p<0.05). Serum HDL‐cholesterol levels were not significantly different between the two groups. AI of the myricetin group was significantly lower than the control group. These results indicate that myricetin could be beneficial in management of type 2 diabetes by controlling dyslipidemia. This research was supported by Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education, Science and Technology (2012015763).